ReviewCancer imaging : the official publication of the International Cancer Imaging Society2022
Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer.
Review in Cancer imaging : the official publication of the International Cancer Imaging Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Review
- PET-guided therapy: synergies, strategies, and future directions in external beam radiation therapy and radiopharmaceutical therapy.Frontiers in medicine · 2026Review
- Combined radioligand therapy and immunotherapy for cancer: research advances and translational challenges.Frontiers in pharmacology · 2026Review
- The tumour sink effect onCancer imaging : the official publication of the International Cancer Imaging Society · 2025Observational
- On the reduction of imaging time-points for dosimetry in radionuclide therapy.EJNMMI physics · 2025Article
- Identifying and navigating bottlenecks in the translation of novel radiopharmaceuticals: a perspective.European journal of nuclear medicine and molecular imaging · 2025Article
- Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells.Theranostics · 2025Article
- Bias and precision of SPECT-basedEJNMMI physics · 2024Article
- Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy.Precision radiation oncology · 2024Review
- Pareto optimization of SPECT acquisition and reconstruction settings forEJNMMI physics · 2024Article
- ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner-Collimator Configurations forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Theranostic digital twins: Concept, framework and roadmap towards personalized radiopharmaceutical therapies.Theranostics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Theranostics - i.e., the combination of molecular imaging and radiopharmaceutical therapy of cancer targeting a common biological feature - is a rapidly expanding field owing the recent successes of novel radiopharmaceutical therapies, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.